Table 3. Individual study characteristics for studies 7–11.

Study Number	Title	Author(s)	Current Status	Results published?	Study design	Sample size	Population	Intervention (plus standard care)	Comparison	Primary Outcome	Setting
7	Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment [34]	Brown J et al.	Completed	No	Non-randomised, safety/efficacy study, open label, single group assignment, phase 1/2 pilot treatment trial	6 in total (4 in intervention arm, 2 in control arm). Target in protocol was 70.	Persons with PCR-confirmed Ebola virus, >18 years old, excluding pregnant women	Convalescent Plasma	Optimised standard of care alone	Change in viral load and Ebola Virus antibody levels	Liberia
8	A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease [35]	Winkler A et al.	Enrolling by invitation	No but publication plan is in development	Non-randomised, safety/efficacy study, single group assignment, open label, phase I treatment trial	Enrolling by invitation (target in protocol was 12). Ebola survivors have consented to donate but no one enrolled to receive INTERCEPT plasma transfusion.	Persons with PCR- confirmed Ebola virus	INTERCEPT plasma	None	Proportion of subjects who survive Ebola (through hospital discharge up to one year)	United States
9	Treating the Host Response to Ebola Virus Disease with Generic Statins and Angiotensin Receptor Blockers [36]	Fedson D et al.	Completed	No (authors state that health officials in Sierra Leone have not released reports of treatment results)	Treating patients consecutively.	Approximately 100 patients were treated consecutively	Persons with confirmed Ebola virus	Atorvastatin and irbesartan	Historical controls receiving standard care alone	Mortality	Sierra Leone
10	Efficacy of Favipiravir (T-705) in patients infected with Ebola virus in Sierra Leone: a preliminary clinical trial [37]	Jiafu J et al.	Completed	No	Non-randomised, double-blind trial. No trial phase stated.	According to protocol: 85 in control group, 39 in intervention group	Persons with PCR- confirmed Ebola virus, aged >9 and <66 years old. Excluding pregnant women.	Favipiravir	WHO-recommended therapies	Death and survival	Sierra Leone
11	Convalescent plasma for early Ebola virus disease in Sierra Leone [38]	Semple C et al.	Completed	No	Emergency, non-randomized safety/efficacy study, phase 2/3, open-label clinical trial, control receives Ringer's lactate infusion.	4 patients (3 in intervention arm). Completed but results not yet published (target in protocol was 300)	Persons with PCR- confirmed Ebola virus, all ages.	Convalescent Plasma	Single intravenous bolus of Ringer's Lactate	All-cause mortality at day 14 post intervention	Sierra Leone